VIEWS: 1 PAGES: 32 CATEGORY: Market and Industry Reports POSTED ON: 11/10/2011
Welichem Biotech Inc. – Product Pipeline Review – Q1 2011
Global Market Direct’s pharmaceuticals report, “Welichem Biotech Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
- Welichem Biotech Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Welichem Biotech Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Welichem Biotech Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Welichem Biotech Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Welichem Biotech Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Welichem Biotech Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Welichem Biotech Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities b
Welichem Biotech Inc. – Product Pipeline Review – Q1 2011 Reference Code: GMDHC1214CDB Publication Date: MAY 2011 Welichem Biotech Inc. – Product Pipeline Review – Q1 2011 GMDHC1214CDB / Published MAY 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Welichem Biotech Inc. – Product Pipeline Review Ta b le o f Co n te n ts Table of Contents 2 List of Tables 3 List of Figures 4 Welichem Biotech Inc. Snapshot 5 Welichem Biotech Inc. Overview 5 Key Information 5 Key Facts 5 Welichem Biotech Inc. – Research and Development Overview 6 Key Therapeutic Areas 6 Welichem Biotech Inc. – Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products – Monotherapy 10 Pipeline Products – Combination Treatment Modalities 11 Welichem Biotech Inc. – Pipeline Products Glance 12 Welichem Biotech Inc. Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Welichem Biotech Inc.–Early Stage Pipeline Products 14 Pre-Clinical Products/Combination Treatment Modalities 14 Welichem Biotech Inc. – Drug Profiles 15 WBI-1001 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 WBI-2100 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 WBI-2100 + Cisplatin 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 WBI-2100 + Dacarbazine 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 WBI-2100 + Gemcitabine 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 WBI-2100 + Taxol 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Welichem Biotech Inc. – Pipeline Analysis 21 Welichem Biotech Inc. – Pipeline Products by Therapeutic Class 21 Welichem Biotech Inc. – Product Pipeline Review – Q1 2011 GMDHC1214CDB / Published MAY 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2) Welichem Biotech Inc. – Product Pipeline Review Welichem Biotech Inc. - Pipeline Products By Target 23 Welichem Biotech Inc. – Pipeline Products by Route of Administration 24 Welichem Biotech Inc. – Pipeline Products by Molecule Type 25 Welichem Biotech Inc. – Recent Pipeline Updates 26 Welichem Biotech Inc. – Locations And Subsidiaries 27 Head Office 27 Financial Deals Landscape 28 Welichem Biotech Inc., Deals Summary, 2004 to 2011 28 Welichem Biotech Inc. Detailed Deal Summary 29 Equity Offering 29 Welichem Biotech Completes Non-Brokered Private Placement Of $3.46 Million 29 Appendix 31 Methodology 31 Coverage 31 Secondary Research 31 Primary Research 31 Expert Panel Validation 32 Contact Us 32 Disclaimer 32 Lis t o f Ta b le s Welichem Biotech Inc. – Pipeline by Therapy Area and Indication, 2011 7 Welichem Biotech Inc. – Pipeline by Stage of Development, 2011 9 Welichem Biotech Inc. – Monotherapy Products in Pipeline, 2011 10 Welichem
Pages to are hidden for
"Welichem Biotech Inc. – Product Pipeline Review – Q1 2011"Please download to view full document